| TEST CHANGE |  |
| :---: | :---: |
| Lacosamide, Serum or Plasma |  |
| 2003182, LACOSA SP |  |
| Specimen Requirements: |  |
| Patient Preparation: | Timing of specimen collection: Pre-dose (trough) draw - At steady state concentration. |
| Collect: | Plain red. Also acceptable: Lavender (K2 or K3EDTA) or pink (K2EDTA). |
| Specimen Preparation: | Separate serum or plasma from cells within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL ) |
| Transport Temperature: | Refrigerated: Also acceptable: Room temperature or frozen. |
| Unacceptable Conditions: | Whole blood. Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution). |
| Remarks: |  |
| Stability: | Ambient: $\mathbf{7 2}$ hours 15 days; Refrigerated: 2 weeks 15 days; Frozen: 2 weeks 15 days |
| Methodology: | QuantitativeHigh Performance Liquid Chromatography-Tandem Mass Spectrometry |
| Performed: | Mon-FriSun-Sat |
| Reported: | 1-4 days |
| Note: |  |
| CPT Codes: | 80235 |
| New York DOH Approval Status: | This test is New York DOH approved. |
| Interpretive Data: |  |
| Lacosamide is an anticonvulsant drug indicated for adjunctive therapy for partial-onset seizures. The therapeutic range is based on serum, predose (trough) draw collection at steady-state concentration. Adverse effects may include dizziness, fatigue, nausea, vomiting, blurred vision, and tremor. |  |
| This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes. |  |
| Reference Interval: |  |

Effective November 15, 2021

| Therapeutic | Not well |
| :---: | :---: |
| Range: | established. |
|  | Suggested range |
| Toxic Level | Greater than or equal to 20 $\mathrm{ug} / \mathrm{mL}$ |

